PhaseRx, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported the net loss of $2.8 million, or $0.23 per share compared to a net loss of $3.3 million, or $0.29 per share for the quarter ended September 30, 2016. Loss from operations was $2,535,000 compared to $3,138,000 a year ago. For the nine months, the net loss was $10.4 million or $0.89 per share compared to $16.7 million or $2.72 per share for the nine months ended September 30, 2016. Loss from operations was $9,770,000 compared to $15,062,000 a year ago.